Clover Health (CLOV) Q2 2026 Earnings Call Transcript
Clover Health (CLOV) reported Q2 2026 results on an earnings call. It said Medicare Advantage membership rose to 157,309 (+48% YoY), revenue was $743.2M (+55.6%), GAAP net income was $28M, and non-GAAP adjusted EBITDA was $40.9M. FY2026 guidance was raised to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA.
How this was made
The 30-second read
Why it matters
The key trading signal is the broad upward revision to FY2026 guidance alongside improving profitability metrics (GAAP net income, adjusted EBITDA, gross profit) and cash generation, tempered by CMS appeal risk to the 2027 star rating and ongoing medical cost trend uncertainty.
Market read
Traders can update models immediately using the raised FY2026 revenue, adjusted EBITDA, and GAAP net income guidance, plus the BER and cash flow improvements, while monitoring CMS appeal and medical trend commentary.
What to watch
General and administrative expenses increased and outpatient trends were described as still elevated versus prior years, which could pressure margins even with improved BER.
Background
Clover Health reported Q2 2026 results and discussed Medicare Advantage membership growth, cohort maturation, and its Clover Assistant AI platform.
Ticker impact
Clover raised FY2026 revenue to $2.92B-$3.0B and adjusted EBITDA to $70M-$85M, citing improved Medicare Advantage cohort economics.
Near-term bias higher as traders reprice FY2026 profitability and cash generation; upside may be capped by CMS appeal and elevated outpatient trends.
The article discloses multiple fresh, decision-relevant datapoints: raised revenue, raised adjusted EBITDA, improved GAAP net income guidance, and cash/operating cash flow strength, partially offset by CMS appeal intent and medical trend uncertainty.
Market effects
Medicare Advantage insurers may see read-across on cohort maturation, BER improvement, and AI-enabled admin/clinical workflows as a profitability lever.
Focus on core markets in New Jersey and Georgia may influence local MA competitive expectations, though the article provides no new regional policy changes.
Limited direct global impact; primarily US Medicare Advantage reimbursement and managed-care profitability dynamics.
Counterpoint
Raised guidance could still be vulnerable if outpatient medical trends re-accelerate or if CMS star-rating appeal changes the payment-year economics.
Key entities
- companyClover Health Investments, Corp.
Subject of the earnings call transcript, providing Q2 results and raised FY2026 guidance.
- regulatorCMS
Centers for Medicare and Medicaid Services, involved in the court-ordered star rating recalculation and an announced intent to appeal.
- technologyClover Assistant
Proprietary AI platform used to support clinical decision-making and back-office insurance operations.
